Advent International, a global private equity firm, Thursday announced the plan to merge two of its pharmaceutical portfolio companies, Cohance Lifesciences Ltd and Suven Pharmaceuticals ..
Suven has been 50% owned by Advent since 2022 acquisition, with the remaining with public and institutional shareholders while Cohance is wholly owned by the PE group. Now post merger, Advent will own 66.7% in the combined entity and the public shareholders the rest.
How PE firms are transitioning from investors to managing companies thehindubusinessline.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thehindubusinessline.com Daily Mail and Mail on Sunday newspapers.
Suven Pharma Q2 profit at Rs 79.56 crore, revenue down 17% on inventory destocking globally financialexpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialexpress.com Daily Mail and Mail on Sunday newspapers.
Suven Pharma Q2 net rises 10%, inventory de-stocking impacts revenue thehindu.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thehindu.com Daily Mail and Mail on Sunday newspapers.